(0.31%) 5 115.92 points
(0.30%) 38 356 points
(0.37%) 15 987 points
(-0.97%) $83.04
(5.36%) $2.03
(0.30%) $2 354.20
(0.54%) $27.68
(4.27%) $961.50
(-0.28%) $0.932
(-0.45%) $10.98
(-0.60%) $0.796
(1.63%) $93.37
@ $45.58
発行日: 14 2月 2024 @ 23:32
リターン: -9.62%
前回のシグナル: 2月 14 - 05:04
前回のシグナル:
リターン: 1.54 %
Live Chart Being Loaded With Signals
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics...
Stats | |
---|---|
本日の出来高 | 203 823 |
平均出来高 | 709 959 |
時価総額 | 3.08B |
EPS | $0 ( 2024-03-05 ) |
次の収益日 | ( $-0.530 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -21.02 |
ATR14 | $0.0540 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Hata Yujiro S | Buy | 480 000 | Stock Option (right to buy) |
2024-03-01 | Ruiz Briseno Andres | Buy | 85 000 | Stock Option (right to buy) |
2024-03-01 | Beaupre Darrin | Buy | 160 000 | Stock Option (right to buy) |
2024-03-01 | White Michael Anthony | Buy | 140 000 | Stock Option (right to buy) |
2024-03-01 | Throne Jason | Buy | 125 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
41.90 |
Last 100 transactions |
Buy: 2 399 671 | Sell: 963 791 |
ボリューム 相関
IDEAYA Biosciences Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
IDEAYA Biosciences Inc 相関 - 通貨/商品
IDEAYA Biosciences Inc 財務諸表
Annual | 2023 |
収益: | $23.39M |
総利益: | $19.38M (82.86 %) |
EPS: | $-1.960 |
FY | 2023 |
収益: | $23.39M |
総利益: | $19.38M (82.86 %) |
EPS: | $-1.960 |
FY | 2022 |
収益: | $50.93M |
総利益: | $48.83M (95.87 %) |
EPS: | $-1.320 |
FY | 2021 |
収益: | $27.94M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.410 |
Financial Reports:
No articles found.
IDEAYA Biosciences Inc
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。